- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-3635
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer ; volume:4 ; number:1 ; day:8 ; month:3 ; year:2019 ; pages:1-10 ; date:12.2019
Signal transduction and targeted therapy ; 4, Heft 1 (8.3.2019), 1-10, 12.2019
- Creator
-
Vyse, Simon
Huang, Paul H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-019-0038-9
- URN
-
urn:nbn:de:101:1-2019033121260069373808
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vyse, Simon
- Huang, Paul H.
- SpringerLink (Online service)
Other Objects (12)
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
EGFR exon 20 insertion mutations in NSCLC
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer